Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Via Krishan Maggon 
Scoop.it!
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world. Via Krishan Maggon
Krishan Maggon 's curator insight,
November 21, 2014 4:03 AM
Uptake and Presentation of Myelin Basic Protein by Normal Human B CellsMarie Klinge Brimnes, Bjarke Endel Hansen, Leif Kofoed Nielsen, Morten Hanefeld Dziegiel, Claus Henrik Nielsen mail Published: November 17, 2014DOI: 10.1371/journal.pone.0113388
|
Scoop.it!
B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Via Krishan Maggon
Krishan Maggon 's curator insight,
January 28, 2015 10:45 AM
Acta Neuropathol Commun. 2014 Sep 16;2:138. doi: 10.1186/s40478-014-0138-2.Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood.Hohmann C, Milles B, Schinke M, Schroeter M, Ulzheimer J, Kraft P, Kleinschnitz C, Lehmann PV, Kuerten S. Acta Neuropathologica Communications 2014, 2:138 doi:10.1186/s40478-014-0138-2 The electronic version of this article is the complete one and can be found online at:http://www.actaneurocomms.org/content/2/1/138
© 2014 Hohmann et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Scoop.it!
Highlights
• Ruth Arnon and Michael Sela profoundly influenced the development of a model system to test new therapies in multiple sclerosis. • By measuring clinical, pathologic, and immunologic outcomes, the biological implications of new drugs could be elucidated. • The pioneering research on Copaxone using the EAE model, paved the way for the discovery of other therapeutics in MS. Via Krishan Maggon
Krishan Maggon 's curator insight,
October 24, 2014 4:24 AM
Journal of Autoimmunity Volume 54, November 2014, Pages 1–7 Honoring the contributions of Ruth Arnon and Michael Sela Review From defining antigens to new therapies in multiple sclerosis: Honoring the contributions of Ruth Arnon and Michael SelaLawrence Steinmana, , Yehuda Shoenfeldb, , , DOI: 10.1016/j.jaut.2014.08.001 |
Cytokine
Volume 73, Issue 2, June 2015, Pages 236–244
Review Article Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10Sara J. Irelanda, 1, 3, , Nancy L. Monsona, 2, 3, , , Laurie S. Davisb, , 3, Show moreChoose an option to locate/access this article:Check if you have access through your login credentials or your institutionCheck access Purchase $35.95 doi:10.1016/j.cyto.2015.01.009